2024
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Monette A, Warren S, Barrett J, Garnett-Benson C, Schalper K, Taube J, Topp B, Snyder A. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee. Journal For ImmunoTherapy Of Cancer 2024, 12: e009427. PMID: 39032943, PMCID: PMC11261685, DOI: 10.1136/jitc-2024-009427.Peer-Reviewed Original ResearchConceptsProgrammed cell death protein 1/programmed death-ligand 1PD-(L)1Biomarker developmentApplication of novel biomarkersPD-(L)1 therapyDeath-ligand 1Patient selection strategiesCombination therapyTumor typesTreatment optionsImmune biologyAxis inhibitionEffective treatmentCancer progressionNovel biomarkersPatientsTherapyImmunotherapyBiomarkersKnowledge of mechanismsDelivery of effective treatmentTreatmentAgentsTumorProgression
2023
Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy
Biswas S, Kang K, Ng K, Radivoyevitch T, Schalper K, Zhang H, Lindner D, Thomas A, MacPherson D, Gastman B, Schrump D, Wong K, Velcheti V, Saunthararajah Y. Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy. Cell Reports 2023, 42: 113016. PMID: 37597186, PMCID: PMC10528072, DOI: 10.1016/j.celrep.2023.113016.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerNon-cytotoxic therapiesImmune checkpoint inhibitorsCell lung cancerDNA methyltransferase 1SCLC cellsCytotoxic chemotherapyLung cancerDisseminated small cell lung cancerRepression marksSurvival of miceLineage commitmentCheckpoint inhibitorsResistant therapiesMaster transcription factorMaturation arrestTherapyTranscription factorsClinical compoundsMethyltransferase 1DNMT1 knockdownChemotherapyLineage maturationTranslocation 2Neuroendocrine lineage
2018
Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma
Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.Peer-Reviewed Original ResearchClinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer
Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst R. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2018, 13: 831-839. PMID: 29578107, PMCID: PMC6485248, DOI: 10.1016/j.jtho.2018.03.008.Peer-Reviewed Original ResearchConceptsPD-1 axis inhibitorsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerInhibitor therapyLocal therapyLymph nodesLung cancerSurvival rateSolid Tumors v1.1Response Evaluation CriteriaSite of diseaseProgression of diseaseProgressive diseaseClinical patternLN metastasisSuch patientsClinical featuresMedian timeRadiographic featuresTumor regressionProlonged benefitPatientsTherapyResponse criteria
2017
MA09.06 Viagenpumatucel-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data from the DURGA Trial
Morgensztern D, Harb W, Schalper K, Price M, Early B, Schreiber T. MA09.06 Viagenpumatucel-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data from the DURGA Trial. Journal Of Thoracic Oncology 2017, 12: s394-s395. DOI: 10.1016/j.jtho.2016.11.447.Peer-Reviewed Original ResearchP2.01-046 Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy
Altan M, Pelekanou V, Schalper K, Toki M, Herbst R, Rimm D. P2.01-046 Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy. Journal Of Thoracic Oncology 2017, 12: s813-s814. DOI: 10.1016/j.jtho.2016.11.1098.Peer-Reviewed Original Research
2016
Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial.
Morgensztern D, Harb W, Schalper K, Price M, Early B, Schreiber T. Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial. Journal Of Clinical Oncology 2016, 34: tps9102-tps9102. DOI: 10.1200/jco.2016.34.15_suppl.tps9102.Peer-Reviewed Original ResearchPredictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research
Schalper KA, Kaftan E, Herbst RS. Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clinical Cancer Research 2016, 22: 2102-2104. PMID: 26957559, PMCID: PMC4940186, DOI: 10.1158/1078-0432.ccr-16-0169.Peer-Reviewed Original Research
2015
The effect of BCG intravesical therapy and recurrence on PDL1 expression in non-invasive bladder cancers.
Hurwitz M, Adeniran A, Yao X, Hafez N, Schalper K, Rimm D, Petrylak D. The effect of BCG intravesical therapy and recurrence on PDL1 expression in non-invasive bladder cancers. Journal Of Clinical Oncology 2015, 33: e15504-e15504. DOI: 10.1200/jco.2015.33.15_suppl.e15504.Peer-Reviewed Original Research